Condition: Pancreatic Cancer Non-resectable · Sponsor: Englewood Hospital and Medical Center
The purpose of this study is to evaluate the short and intermediate term safety of the NanoKnife Irreversible Electroporation System when used off-label to treat unresectable pancreatic cancer. In addition, the study will evaluate the efficacy of this device in treating pain associated with unresectable pancreatic cancer. Quality of life post-procedure will also be collected.
This description comes directly from the study's public registry record.
Cherif Boutros · (201) 608-2266 · Cherif.Boutros@EHMCHealth.org
Jamie Ketas · 201-894-3418 · jamie.ketas@ehmchealth.org
Always discuss trial participation with your own doctor first.
| Englewood Hospital | Englewood, New Jersey, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06937996